ATAI Life SciencesATAI
ATAI
About: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Employees: 83
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
70% more call options, than puts
Call options by funds: $134K | Put options by funds: $79K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
1.88% less ownership
Funds ownership: 8.79% [Q2] → 6.91% (-1.88%) [Q3]
16% less funds holding
Funds holding: 88 [Q2] → 74 (-14) [Q3]
32% less capital invested
Capital invested by funds: $19.6M [Q2] → $13.4M (-$6.2M) [Q3]
48% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 23
63% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 19
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
545%
upside
Avg. target
$10.50
577%
upside
High target
$11
610%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 37% 1-year accuracy 63 / 171 met price target | 545%upside $10 | Buy Reiterated | 29 Jan 2025 |
Canaccord Genuity Sumant Kulkarni 28% 1-year accuracy 9 / 32 met price target | 610%upside $11 | Buy Maintained | 18 Nov 2024 |
Financial journalist opinion
Based on 6 articles about ATAI published over the past 30 days
Positive
Seeking Alpha
2 days ago
Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst
Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients, showing a 50% abstinence in patients over a 12-week period. Release of results from the phase 2b study using BPL-003 for treatment-resistant depression expected in mid-2025. The global treatment-resistant depression treatment market is projected to reach $4.06 billion by 2030.
Positive
Proactive Investors
3 days ago
atai Life Sciences poised for near-term value creation with release of psychedelics trial data: analysts
atai Life Sciences could create value in the near-term with the release of key Phase 2 and 3 datasets for psychedelic drug candidates over the next 12 to 18 months, analysts at Jefferies believe. “Seeing positive data could strengthen the notion psychedelics have an important role for hard-to-treat $1 billion-plus central nervous systems disorders, as well as reassure investors the FDA's rejection of MDMA in 2024 was more of an idiosyncrasy,” analysts wrote in a note to clients.
Positive
Proactive Investors
3 days ago
atai Life Sciences unveils positive results from Beckley Psytech's alcohol use disorder trial
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced positive topline results from Beckley Psytech's Phase 2a study of BPL-003 (intranasal 5-MeO-DMT benzoate) in alcohol use disorder. The company said a single dose of BPL-003 in combination with relapse prevention therapy produced “meaningful and sustained reductions” in alcohol use, with the mean number of alcohol units consumed per day decreasing from 9.3 units to 2.2 units.
Positive
Proactive Investors
4 days ago
Spravato sales surged highlights commercial viability of psychedelics, analysts believe
The latest quarterly sales figures for Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray support the notion that psychedelics can become commercially viable for mental health, analysts at Jefferies believe. Fourth quarter Spravato sales grew by 5% quarter-over-quarter to $297 million driven by increased physician and patient demand.
Positive
Proactive Investors
3 weeks ago
atai Life Sciences announces leadership appointments to advance psychedelic therapeutics pipeline
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced several key leadership appointments to advance its aim of delivering innovative mental health therapies. Dr Srinivas Rao has officially transitioned to the role of sole chief executive officer, following his promotion to co-CEO in mid-2024.
Neutral
GlobeNewsWire
3 weeks ago
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer - Kevin Craig, M.D. promoted to Chief Medical Officer - Glenn Short, Ph.D. promoted to Chief Scientific Officer - Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer
Positive
Proactive Investors
2 months ago
atai Life Sciences shares set to be lifted by 2025 trial data readouts: analysts
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares should move higher on a slew of Phase 2 and 3 data readouts in 2025 from across its pipeline of innovative psychedelic therapies, analysts at Jefferies. Following the release of atai's third quarter results earlier this week, the analysts repeated their ‘Buy' rating on the stock and awarded it a $5 price target, implying upside of 242% from its share price at the time of writing.
Positive
Proactive Investors
2 months ago
atai Life Sciences advances therapeutic pipeline in Q3 with FDA approval of VLS-01
atai Life Sciences (NASDAQ:ATAI, ETR:9VC), a biopharmaceutical company targeting mental health disorders, advanced its pipeline of innovative therapies during the third quarter of 2024. Notably, the US Food and Drug Administration approved an investigational new drug application for for VLS-01, atai's buccal film formulation of DMT.
Positive
Proactive Investors
2 months ago
RFK Jr's appointment in health could accelerate psychedelic drug development, analysts say
President-elect Donald Trump's promise that Robert F Kennedy Junior (RFK Jr) will take on a “big role” in shaping health policy could be a positive for psychedelics given RKF Jr's well-documented support of this drug class, analysts at Jefferies believe. “RFK Jr seems positively inclined and sounds motivated to help foster psychedelic drug development,” analysts wrote in a note to clients, noting that psychedelics have reportedly helped his family and friends recover from trauma, severe depression and obsessive-compulsive disorder.
Neutral
GlobeNewsWire
3 months ago
IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG
MONTRÉAL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, announces that the Company and its subsidiary IntelGenx Corp. (“IGX” and, together with the Company, the “IGX Entities”) have obtained on September 30, 2024 an approval and vesting order (the “Approval and Vesting Order”) from the Superior Court of Québec (Commercial Division) (the “Court”) issued in connection with the previously announced proceedings instituted pursuant to the Companies' Creditors Arrangement Act (the “CCAA”).
Charts implemented using Lightweight Charts™